Vivani Medical, Inc. (VANI)

NCM – Real vaqt narxi. Valyuta: USD

1.20

+0.06 (5.26%)

Yopilishda: Jun 26, 2026, 4:00 PM EDT

1.19

-0.01 (-0.83%)

Bozordan keyin: Jun 26, 2026, 4:39 PM EDT

13.05.2026

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivalents, restricted cash and capital commitments expected to fund current operating plan through the first half of 2027 ALAMEDA, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implants utilizing its proprietary NanoPortal™ technology, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

03.04.2026

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?

Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

26.03.2026

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026.

29.01.2026

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. (“Cortigent”), its wholly-owned subsidiary developing brain implant devices, presented the results of a 6-year Early Feasibility Study of the Orion® Visual Cortical Prosthesis System under development to deliver meaningful visual perception to blind persons at the North American Neuromodulation Society (“NANS”) annual meeting.

27.01.2026

Vivani Medical, Inc. Announces Closing of Common Stock Offering

ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. Gross proceeds from the two transactions were approximately $4.5 million, before deducting fees and offering expenses.

26.01.2026

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. The registered offering and the private placement were priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC. The gross proceeds to the Company from the registered offering and private placement are expected to be approximately $4.5 million, before deducting placement agent fees and estimated offering expenses. The registered offering and private placement are expected to close on or about January 27, 2026, subject to the satisfaction of customary closing conditions.

13.11.2025

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

Company plans to initiate Phase 1 clinical study of semaglutide implant for chronic weight management in the first half of 2026 and parallel investments in studies to enable rapid initiation of Phase 2 dose-ranging study, pending Phase 1 results and regulatory feedback

Videolar

No Data

There is no data to display

Press-relizlar

13.05.2026

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

26.03.2026

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

29.01.2026

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

27.01.2026

Vivani Medical, Inc. (VANI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Vivani Medical, Inc. (VANI)

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Vivani Medical, Inc. Announces Closing of Common Stock Offering

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

Videolar

No Data

Press-relizlar

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Vivani Medical, Inc. Announces Closing of Common Stock Offering

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Vivani Medical, Inc. Announces Closing of Common Stock Offering

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

Videolar

No Data

Press-relizlar

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Vivani Medical, Inc. Announces Closing of Common Stock Offering

Search stocks

Vivani Medical, Inc. (VANI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Vivani Medical, Inc. (VANI)

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Vivani Medical, Inc. Announces Closing of Common Stock Offering

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

Videolar

No Data

Press-relizlar

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Vivani Medical, Inc. Announces Closing of Common Stock Offering

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Vivani Medical, Inc. Announces Closing of Common Stock Offering

Vivani Medical, Inc. Announces Pricing of Common Stock Offering

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

Videolar

No Data

Press-relizlar

Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update

Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

Vivani Medical, Inc. Announces Closing of Common Stock Offering